Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytokinetics, Incorporated on November 13, 2025. The filing discloses the appointment of a new senior executive officer effective November 14, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change is the appointment of Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer. Mr. Hessekiel joins the company from Exelixis, Inc., where he served as Executive Vice President and General Counsel from 2014 to 2025.
Compensation and Management Commentary
The filing details the compensatory arrangements for Mr. Hessekiel:
- Base Salary: $660,000 annually.
- Target Bonus: 50% of base salary ($330,000), split between corporate (75%) and individual (25%) goals.
- Signing Bonus: $400,000 total, payable in two installments (50% at start, 50% at one-year anniversary), subject to repayment clauses.
- Equity Award: Restricted Stock Units (RSUs) with a grant date value of $5,800,000. Vesting schedule: 40% at one year, 40% at two years, and 20% at three years.
- Other Benefits: Participation in standard benefit plans, the 2004 Equity Incentive Plan, and the Executive Severance Plan. A standard indemnification agreement was also executed.
Investor Verification Checklist
- Verify the exact vesting terms and acceleration provisions in the 2004 Equity Incentive Plan and Severance Plan referenced in the filing.
- Confirm the repayment conditions for the signing bonus in the event of voluntary resignation or termination for cause.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 10, 2025) for full details on the Bonus Plan and Severance Plan.
- Check the Form 10-K for the fiscal year ending December 31, 2025, for the full text of the Offer Letter.